| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.9 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | apicidin | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | 0.0089 | 0.9 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.9 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |